Special Issue

Application of Artificial Intelligence-Based Approaches in Cancer Diagnosis, Treatment and Prognosis

Message from the Guest Editor

Advancements in artificial intelligence (AI) have revolutionized various sectors and are rapidly reshaping cancer research and personalized clinical care. Big data and our powerful computing capacity have led to the transformative potential of AI-based approaches, particularly deep learning and generative AI, in the field of oncology, specifically in cancer diagnosis, treatment, and prognosis. This Special Issue invites research on AI-based diagnostic tools, including imaging, histopathology, and biomarker identification, as well as AI-assisted treatment planning for radiotherapy, chemotherapy, and immunotherapy. Studies on AI models predicting treatment responses, personalizing therapies, and managing side effects are encouraged. Contributions on generative AI for drug discovery, simulating interactions, and predicting novel compounds are also sought. Additionally, we welcome multimodal AI algorithms integrating pathology, radiology, genomics, and medical records to enhance prognostic insights, patient monitoring, follow-up care, and long-term outcome predictions. I look forward to receiving your contributions.

Guest Editor

Dr. Wei Wu

Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA

Deadline for manuscript submissions

30 June 2026

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/217292

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)